
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
An inefficient practice that is plagued with flow problems, stemming from a poorly organized scheduling system, can be remedied with simple solutions